Erythrocyte Transport of Lactate During Exercise (TELE Project)
Transporte Eritrocitario de Lactato en Ejercicio
Technical University of Madrid
84 participants
Feb 3, 2020
INTERVENTIONAL
Conditions
Summary
The goals of this clinical trial are: 1. to study lactate kinetic between plasma and erythrocytes during an intervallic exercise and its subsequent recovery, considering the blood pH, the genotype for the T1470A polymorphism of the SLC16A1 gene (rs1049434), and the amount of MCT1 in erythrocytes membrane; 2. to analyze the levels of MCT1 in the erythrocytes membrane according to training status and genotype for the T1470A polymorphism of SLC16A1 (rs1049434). For this, the project will have two phases: * In phase I, trained participants will perform one maximal incremental test and one intervallic submaximal test with a final active recovery. * Phase II, levels of the MCT1 protein in the erythrocyte membrane will be quantified from trained and sedentary participants.
Eligibility
Inclusion Criteria4
- BMI between 18 and 25 kg/m2
- Not smoker
- In the case of trained participants: training at least 5 hours/week, of which at least 3 must be aerobic/anaerobic endurance training. Presentation of a medical certificate attesting to their medical fitness (capability) to perform intense physical exercise.
- In the case of sedentary participants, less than 1 day of training per week or less than 2 hours of structured exercise per week.
Exclusion Criteria2
- Presenting any pathology that could impede the correct performance of the tests, or could influence the main study variables.
- In the case of the female sample, having irregular menstrual cycles, oligomenorrhea or amenorrhea.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06104150